SCHEMBL6315672

SCHEMBL6315672

C=CCNC(=O)c1c(-c2sccc2C)noc1N

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.41
LMNA P02545 5/20 0.39
SMN1; SMN2 Q16637 5/20 0.38
RAB9A P51151 3/20 0.38
NPC1 O15118 2/20 0.38
STAT1 P42224 1/20 0.38
HPGD P15428 4/20 0.38
ALDH1A1 P00352 4/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
GFER P55789 1/20 0.37
MEN1 O00255 1/20 0.36
ALOX15 P16050 1/20 0.36
KMT2A Q03164 1/20 0.36
HSD17B10 Q99714 1/20 0.36
CYP2C9 P11712 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6322906 0.83 GAA (0.42) POLBLMNASMN1; SMN2RAB9ANPC1
SCHEMBL6324184 0.82 ALDH1A1 (0.44) POLBLMNASMN1; SMN2RAB9ANPC1
SCHEMBL6315404 0.81 KMT2A (0.47) POLBLMNASMN1; SMN2HPGDALDH1A1
SCHEMBL6318769 0.81 NPSR1 (0.42) POLBSMN1; SMN2RAB9ANPC1HPGD
SCHEMBL6316911 0.81 MEN1 (0.45) POLBLMNASMN1; SMN2RAB9ANPC1
SCHEMBL6318418 0.81 POLB (0.53) POLBLMNASMN1; SMN2RAB9ANPC1
SCHEMBL6317656 0.81 GAA (0.42) POLBLMNASMN1; SMN2RAB9ANPC1
SCHEMBL6317489 0.81 GAA (0.41) POLBLMNASMN1; SMN2HPGDALDH1A1
SCHEMBL6316236 0.81 GAA (0.41) POLBLMNASMN1; SMN2HPGDALDH1A1
SCHEMBL6318143 0.81 POLB (0.49) POLBLMNANPC1HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 POLB 872/4885LMNA 3334/4885SMN1; SMN2 2766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.